Aim: It has been reported that beta-blockers (
BB
) reduce cardiovascular events in patients with atherosclerotic disease. However, little is known about the efficacy of these drugs in patients with critical limb ischemia (CLI). We investigated whether beta-blocker therapy affects the clinical outcomes of CLI patients.
Methods: Between March 2004 and December 2011, 1,873 consecutive CLI patients who received endovascular therapy (EVT) (394
BB
-treated patients and 1,479 non-
BB
-treated patients) for de novo infrainguinal lesions were identified retrospectively. A propensity score analysis was used for risk adjustment in a multivariable analysis and one-to-one matching (
BB
: 305, non-
BB
305). The primary endpoint was amputation-free survival (AFS), and the secondary endpoints were overall survival and the rates of limb salvage and freedom from major adverse limb events (MALE; including repeat reintervention, surgical conversion and major amputation). The mean follow-up period was
22
±15 months.
Results: In the propensity score-matched pair analysis, there were no significant differences in AFS between the patients treated with and without beta-blockers (58.8% vs. 58.
5
% at three years, log-rank
p=
0
.76). There were also no significant differences in the limb salvage rate (88.3% vs. 88.8 at three years, log-rank
P=
0
.41), overall survival (63.
0
% vs. 62.
4
% at three years, log-rank
P=
0
.70) and freedom from MALE (43.6% vs. 44.
9
% at three years, log-rank
P=
0
.58) between the patients treated with and without beta-blockers.
Conclusions: The present results suggest that beta-blocker therapy does not worsen the clinical outcomes after EVT in CLI patients.
抄録全体を表示